Bone metastases from advanced cancers: Clinical implications and treatment options

Clinical Journal of Oncology Nursing

Volumn 13, Issue 6, 2009, Pages 701-710

  Fitch, Margaret ^a   Maxwell, Cathy ^b   Ryan, Claire ^c   Löthman, Helen ^d   Drudge Coates, Lawrence ^e   Costa, Luis ^f  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b Advanced Medical Specialties   (United States)

^c MAIDSTONE AND TUNBRIDGE WELLS NHS TRUST   (United Kingdom)

^d Sophiahemmet Hospital   (Sweden)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BONE TUMOR; BREAST TUMOR; FEMALE; HUMAN; METASTASIS; PAIN; PALLIATIVE THERAPY; PATHOLOGY; PATHOPHYSIOLOGY; QUALITY OF LIFE;

BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; PAIN; PALLIATIVE CARE; QUALITY OF LIFE;

EID: 77449157439     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/09.CJON.701-710     Document Type: Article

References (72)

1. Berenson, J.R. (2005). Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist, 10(1), 52-62.
2. Berenson, J.R., Lichtenstein, A., Porter, L., Dimopoulos, M.A., Bordoni, R., George, S., et al. (1998). Long-term Pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. Journal of Clinical Oncology, 16(2), 593-602.
3. Berenson, J.R., Rajdev, L., & Broder, M. (2006). Pathophysiology of bone metastases. Cancer Biology and Therapy, 5(9), 1078-1081.
4. Body, J.J., Diel, I.J., Bell, R., Pecherstorfer, M., Lichinitser, M.R., Lazarev, A.F., et al. (2004). Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain, 111(5), 306-312.
5. Body, J.J., Diel, I.J., Lichinitser, M.R., Kreuser, E.D., Dornoff, W., Gorbunova, V.A., et al. (2003). Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Annals of Oncology, 14(9), 1399-1405.
6. Botteman, M., Barghout, V., Stephens, J., Hay, J., Brandman, J., & Aapro, M. (2006). Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Annals of Oncology, 17(1), 1072-1082.
7. Choong, P.F. (2003). Cardiopulmonary complications of intramedullary fixation of long bone metastases. Clinical Orthopaedics and Related Research, October(415, Suppl.), S245-S253.
8. Chow, E., Harris, K., Tharmalingam, S., Bezjak, A., Wu, J., Barton, M., et al. (2007). Early phase in the development of a bone metastases quality of life module. Clinical Oncology, 19(5, Suppl.), S26.
9. Coleman, R.E. (1997). Skeletal complications of malignancy. Cancer, 80(8, Suppl.), 1588-1594.
10. Coleman, R.E. (2004). Bisphosphonates: Clinical experience. Oncologist, 9(Suppl. 4), 14-27.
11. Costa, L., Badia, X., Chow, E., Lipton, A., & Wardley, A. (2008). Impact of skeletal complications on patients' quality of life, mobility, and functional independence. Supportive Care in Cancer, 16(8), 879-889.
12. Cree, M., Soskolne, C.L., Belseck, E., Hornig, J., McElhaney, J.E., Brant, R., et al. (2000). Mortality and institutionalization following hip fracture. Journal of the American Geriatrics Society, 48(5), 283-288.
13. Dearnaley, D.P., Sydes, M.R., Mason, M.D., Stott, M., Powell, C.S., Robinson, A.C., et al. (2003). A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). Journal of the National Cancer Institute, 95(17), 1300-1311.
14. Dimopoulos, M.A., Kastritis, E., Bamia, C., Melakopoulos, I., Gika, D., Roussou, M., et al. (2009). Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Annals of Oncology, 20(1), 117-120.
15. Elomaa, I., Kylmala, T., Tammela, T., Viitanen, J., Ottelin, J., Ruutu, M., et al. (1992). Effect of oral clodronate on bone pain. A controlled study in patients with metastatic prostatic cancer. International Urology and Nephrology, 24(2), 159-166.
16. Ernst, D.S., Tannock, I.F., Winquist, E.W., Venner, P.M., Reyno, L., Moore, M.J., et al. (2003). Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. Journal of Clinical Oncology, 21(17), 3335-3342.
17. Gainor, B.J., & Buchert, P. (1983). Fracture healing in metastatic bone disease. Clinical Orthopaedics and Related Research, 178, 297-302.
18. Göl, D., Höer, A., Schiffhorst, G., Brandman, J., & Haussier, B. (2005). Persistency with oral bisphosphonates in cancer patients [Abstract 8221). Journal of Clinical Oncology, 23(16S), 783S.
19. Groot, M.T., Boeken Kruger, C.G., Pelger, R.C., & Uyl-de Groot, C.A. (2003). Costs of prostate cancer, metastatic to the bone, in the Netherlands. European Urology, 43(5), 226-232.
20. Hatoum, H.T., Lin, S.J., Smith, M.R., Barghout, V., & Lipton, A. (2008). Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: Analysis of a national medical claims database. Cancer, 113(6), 1438-1445.
21. Heidenreich, A., Bolla, M., Joniau, S., van der Kwast, T.H., Matveev, V., Mason, M.D., et al. (2009). European Association of Urology guidelines on prostate cancer. Retrieved November 16, 2009, from http://www.uroweb.org/ fileadmin/tx-eauguidelines/2009/ Full/Prostate-Cancer.pdf
22. Hillner, B.E., Ingle, J.N., Berenson, J.R., Janjan, N.A., Albain, K.S., Lipton, A., et al. (2000). American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. Journal of Clinical Oncology, 18(6), 1378-1391.
23. Hillner, B.E., Ingle, J.N., Chlebowski, R.T., Gralow, J., Yee, G.C., Janjan, N.A., et al. (2003). American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. Journal of Clinical Oncology, 21(21), 4042-4057.
24. Hoff, A.O., Toth, B.B., Altundag, K., Johnson, M.M., Warneke, C.L., Hu, M., et al. (2008). Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. Journal of Bone and Mineral Research, 23(6), 826-836.
25. Hoffmann-La Roche. (2004). Ostac®(clodronate) [Package insert]. Nutley, NJ: Author.
26. Hortobagyi, G.N., Theriault, R.L., Lipton, A., Porter, L., Blayney, D., Sinoff, C., et al. (1998). Long-term prevention of skeletal complications of metastatic breast cancer with Pamidronate. Protocol 19 Aredia Breast Cancer Study Group. Journal of Clinical Oncology, 16(6), 2038-2044.
27. Hortobagyi, G.N., Theriault, R.L., Porter, L., Blayney, D., Lipton, A., Sinoff, C., et al. (1996). Efficacy of Pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. New England Journal of Medicine, 335(24), 1785-1791.
28. Kohno, N., Aogi, K., Minami, H., Nakamura, S., Asaga, T., lino, Y., et al. (2005). Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial. Journal of Clinical Oncology, 23(15), 3314-3321.
29. Kristensen, B., Ejlertsen, B., Groenvold, M., Hein, S., Loft, H., & Mouridsen, H.T. (1999). Oral clodronate in breast cancer patients with bone metastases: A randomized study. Journal of Internal Medicine, 246(1), 67-74.
30. Kylmala, T., Taube, T., Tammela, T.L., Risteli, L., Risteli, J., & Elomaa, I. (1997). Concomitant i.v. and oral clodronate in the relief of bone pain-A double-blind placebo-controlled study in patients with prostate cancer. British Journal of Cancer, 76(7), 939-942.
31. Lipton, A. (2003). Bisphosphonate therapy in the oncology setting. Expert Opinion on Emerging Drugs, 8(2), 469-488.
32. Lipton, A. (2007). Treatment of bone metastases and bone pain with bisphosphonates. Supportive Cancer Therapy, 4(2), 92-100.
33. Lipton, A., Seaman, J., & Zheng, M. (2004, March 24-26). Efficacy and safety of zoledronic acid in patients with bone metastases from renal cell carcinoma. Poster presented at the What Is New in Bisphosphonates? Seventh Workshop on Bisphosphonates- From the Laboratory to the Patient, Davos, Switzerland.
34. Lipton, A., Theriault, R.L., Hortobagyi, G.N., Simeone, J., Knight, R.D., Mellars, K., et al. (2000). Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials. Cancer, 88(5), 1082-1090.
35. Major, P.P. (2007). Optimal management of metastatic bone disease. European Journal of Oncology Nursing, 77(Suppl. 2), S32-S37.
36. Major, P.P., Cook, R., Chen, B.L., & Zheng, M. (2005). Survivaladjusted multiple-event analysis for the evaluation of treatment effects of zoledronic acid in patients with bone metastases from solid tumors. Supportive Cancer Therapy, 2(4), 234-240.
37. Mangiapane, S., Hoer, A., Gothe, H., Barghout, V., & Haeussler, B. (2006). Higher persistency with i.v. bisphosphonates in patients with bone metastasis [Abstract 18623]- Journal of Clinical Oncology, 24(18 Suppl.), 698s.
38. Maxwell, C. (2007). Role of the nurse in preserving patients' independence. European Journal of Oncology Nursing, 11(Suppl. 2), S38-S41.
39. Maxwell, C., Swift, R., Goode, M., Doane, L., & Rogers, M. (2003). Advances in supportive care of patients with cancer and bone metastases: Nursing implications of zoledronic acid. Clinical Journal of Oncology Nursing, 7(4), 403-408.
40. Mundy, G.R. (1997). Mechanisms of bone metastasis. Cancer, 80(8, Suppl.), 1546-1556.
41. National Comprehensive Cancer Network. (2008). NCCN Clinical Practice Guidelines in Oncology™: Non-small cell lung cancer. [v.2.2008]. Retrieved February 20, 2008, from http://www.nccn .org/professionals/physician-gls/f- guidelines.asp
42. Novartis Pharmaceuticals Corporation. (2008a). Aredia® (Pamidronate disodium) for injection [Package insert]. East Hanover, NJ: Author.
43. Novartis Pharmaceuticals Corporation. (2008b). Zometa® (zoledronic acid) injection concentrate for intravenous infusion [Package insert]. East Hanover, NJ: Author.
44. Oefelein, M.G., Ricchiuti, V., Conrad, W., & Resnick, M.I. (2002). Skeletal fractures negatively correlate with overall survival in men with prostate cancer. Journal of Urology, 168(5), 1005-1007.
45. Paterson, A.H., Powles, T.J., Kanis, J.A., McCloskey, E., Hanson, J., & Ashley, S. (1993). Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. Journal of Clinical Oncology, 11(1), 59-65.
46. Pavlakis, N., Schmidt, R.L., & Stockler, M.R. (2005). Bisphosphonates for breast cancer. Cochrane Database of Systematic Reviews, 1, CD003474.
47. Payne, R. (1989). Pharmacologic management of bone pain in the cancer patient. Clinical Journal of Pain, 5(Suppl. 2), S43-S49.
48. Peng, W.L., Wu, G.J., Sun, WZ., Chen, J.C., & Huang, A.T. (2006). Multidisciplinary management of cancer pain: A longitudinal retrospective study on a cohort of end-stage cancer patients. Journal of Pain and Symptom Management, 32(5), 444-452.
49. Reich, C.D. (2003). Advances in the treatment of bone metastases. Clinical Journal of Oncology Nursing, 7(6), 641-646.
50. Ripamonti, C.I., Maniezzo, M., Campa, T., Fagnoni, E., Brunelli, C., Saibene, G., et al. (2009). Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Annals of Oncology, 20(1), 137-145.
51. Roche. (2006). Boniva® (ibandronate sodium) tablets [Package insert] Nutley, NJ: Author.
52. Roche Products Ltd. (2007). Bondronat® (ibandronate sodium) concentrate for infusion [Package insert]. Welwyn Garden City, United Kingdom: Author.
53. Rosen, L.S., Gordon, D., Kaminski, M., Howell, A., Belch, A., Mackey, J., et al. (2003). Long-term efficacy and safety of zoledronic acid compared with Pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial. Cancer, 98(8), 1735-1744.
54. Rosen, L.S., Gordon, D., Tchekmedyian, N.S., Yanagihara, R., Hirsh, V., Krzakowski, M., et al. (2004). Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, phase III, double-blind, placebo-controlled trial. Cancer, 100(12), 2613-2621.
55. Saad, F. (2002). Treatment of bone complications in advanced prostate cancer: Rationale for bisphosphonate use and results of a phase III trial with zoledronic acid. Seminars in Oncology, 29(6, Suppl. 21), 19-27.
56. Saad, F., Gleason, D.M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., et al. (2002). A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Journal of the National Cancer Institute, 94(19), 1458-1468.
57. Saad, F., GIeason, D.M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., et al. (2004). Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. Journal of the National Cancer Institute, 96(11), 879-882.
58. Saad, F., Lipton, A., Cook, R., Chen, Y.M., Smith, M., & Coleman, R. (2007). Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer, 110(8), 1860-1867.
59. Schulman, K.L., & Kohles, J. (2007). Economic burden of metastatic bone disease in the U.S. Cancer, 109(11), 2334-2342.
60. Schumacher, K.L., Koresawa, S., West, C., Dodd, M., Paul, S.M., Tripathy, D., et al. (2002). The usefulness of a daily pain management diary for outpatients with cancer-related pain. Oncology Nursing Forum, 29(9), 1304-1313.
61. Simmonds, M.A. (1999). Management of breakthrough pain due to cancer. Oncology (Williston Park), 13(8), 1103-1108.
62. Siris, E.S., Harris, S.T., Rosen, C.J., Barr, C.E., Arvesen, J.N., Abbott, T.A., et al. (2006). Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clinic Proceedings, 81(8), 1013-1022.
63. Small, E.J., Smith, M.R., Seaman, J.J., Petrone, S., & Kowalski, M.O. (2003). Combined analysis of two multicenter, randomized, placebo-controlled studies of Pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. Journal of Clinical Oncology, 21(25), 4277-4284.
64. Smith, J.A., Jr. (1989). Palliation of painful bone metastases from prostate cancer using sodium etidronate: Results of a randomized, prospective, double-blind, placebo-controlled study. Journal of Urology, 141(1), 85-87.
65. Strang, P., Nilsson, S., Brandstedt, S., Sehlin, J., Borghede, G., Varenhorst, E., et al. (1997). The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer. Anticancer Research, 17(6D), 4717-4721.
66. Tubiana-Hulin, M., Beuzeboc, P., Mauriac, L., Barbet, N., Frenay, M., Monnier, A., et al. (2001). [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases]. Bulletin du Cancer, 88(7), 701-707.
67. Weinfurt, K.P., Anstrom, K.J., Castel, L.D., Schulman, K.A., & Saad, F. (2006). Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer. Annals of Oncology, 17(6), 986-989.
68. Weinfurt, K.P., Castel, L.D., Li, Y., Timbie, J.W., Glendenning, G.A., & Schulman, K.A. (2004). Health-related quality of life among patients with breast cancer receiving zoledronic acid or Pamidronate disodium for metastatic bone lesions. Medical Care, 42(2), 164-175.
69. Weinfurt, K.P., Li, Y., Castel, L.D., Saad, F., Timbie, J.W., Glendenning, G.A., et al. (2005). The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Annals of Oncology, 16(4), 579-584.
70. Wiktor-Jedrzejczak, W. (2005). Reduction of pain as the primary determinant of improved quality of life of cancer patients receiving zoledronic acid (Zol) for bone involvement [Abstract 8022]. Journal of Clinical Oncology, 23(Suppl.), 734s.
71. Wong, R., & Wiffen, P.J. (2002). Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database of Systematic Reviews, 1, CD002068.
72. Yarbro, C.H., O'Kelly, P., de Mattos Pimenta, C.A., Caponera, R., & Aranda, S. (2003). Advances in bisphosphonate therapy for malignant bone disease. East Hanover, NJ: Novartis Pharmaceuticals Corporation.